Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Pliant Therapeutics (PLRX) Net Income towards Common Stockholders (2019 - 2026)

Pliant Therapeutics has reported Net Income towards Common Stockholders over the past 8 years, most recently at -$20.0 million for Q1 2026.

  • Quarterly Net Income towards Common Stockholders rose 64.32% to -$20.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$111.4 million through Mar 2026, up 49.26% year-over-year, with the annual reading at -$147.5 million for FY2025, 29.86% up from the prior year.
  • Net Income towards Common Stockholders was -$20.0 million for Q1 2026 at Pliant Therapeutics, up from -$21.7 million in the prior quarter.
  • Over five years, Net Income towards Common Stockholders peaked at -$20.0 million in Q1 2026 and troughed at -$57.8 million in Q3 2024.
  • The 5-year median for Net Income towards Common Stockholders is -$41.1 million (2023), against an average of -$39.0 million.
  • Year-over-year, Net Income towards Common Stockholders crashed 42.92% in 2022 and then surged 64.32% in 2026.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$35.1 million in 2022, then fell by 17.25% to -$41.1 million in 2023, then decreased by 20.98% to -$49.7 million in 2024, then skyrocketed by 56.27% to -$21.7 million in 2025, then grew by 7.86% to -$20.0 million in 2026.
  • Per Business Quant, the three most recent readings for PLRX's Net Income towards Common Stockholders are -$20.0 million (Q1 2026), -$21.7 million (Q4 2025), and -$26.3 million (Q3 2025).